MedTrace Logo

Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder

NCT00382291 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2013-03-12

Study results available
· View outcomes & findings →

Summary

This study measures the occurrence of certain side effects linked to antidepressant use and evaluates the effectiveness of the medication sertraline plus cognitive behavioral therapy to treat people with obsessive-compulsive disorder.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Regular Titration

Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.

DRUG

Placebo

The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.

DRUG

Slow Titration

Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Tanya K. Murphy, MD · University of South Florida

  • Regina Bussing, M.D. · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382291 on ClinicalTrials.gov